ValuEngine lowered shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a strong sell rating in a report released on Friday morning.

ABUS has been the topic of several other research reports. JMP Securities reaffirmed an outperform rating and issued a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a research note on Wednesday, October 4th. Chardan Capital reaffirmed a buy rating on shares of Arbutus Biopharma in a research note on Wednesday, September 13th. Zacks Investment Research upgraded Arbutus Biopharma from a sell rating to a hold rating in a research report on Tuesday, November 7th. Wedbush reiterated an outperform rating and set a $9.00 target price on shares of Arbutus Biopharma in a research report on Wednesday, September 20th. Finally, BidaskClub cut Arbutus Biopharma from a hold rating to a sell rating in a research report on Saturday, December 2nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $13.00.

Arbutus Biopharma (NASDAQ:ABUS) opened at $4.75 on Friday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 12 month low of $2.35 and a 12 month high of $8.25.

In related news, insider Michael J. Sofia sold 10,000 shares of the stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. purchased a new position in Arbutus Biopharma during the 3rd quarter valued at approximately $1,393,000. RTW Investments LP grew its holdings in Arbutus Biopharma by 1.1% during the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after buying an additional 56,457 shares in the last quarter. OxFORD Asset Management LLP grew its holdings in Arbutus Biopharma by 49.2% during the 3rd quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock valued at $778,000 after buying an additional 40,963 shares in the last quarter. Vanguard Group Inc. grew its holdings in Arbutus Biopharma by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Arbutus Biopharma during the 2nd quarter valued at approximately $478,000. Institutional investors and hedge funds own 59.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Lowers Arbutus Biopharma (ABUS) to Strong Sell” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/19/valuengine-lowers-arbutus-biopharma-abus-to-strong-sell.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.